A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users

Drug and Alcohol Dependence

Volumn 71, Issue 2, 2003, Pages 127-131

  Seal, Karen H ^a,b   Kral, Alex H ^a   Lorvick, Jennifer ^a   McNees, Alex ^a   Gee, Lauren ^a   Edlin, Brian R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Contingency contracting; Hepatitis; Intravenous drug users; Treatment; Vaccination

Indexed keywords

ENERGIX B; HEPATITIS B VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG ABUSE; DRUG DOSE REGIMEN; DRUG USE; FEMALE; HEALTH CARE PERSONNEL; HEPATITIS B; HIGH RISK POPULATION; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MONEY; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

HEPATITIS B VIRUS;

EID: 0142012011     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(03)00074-7     Document Type: Article

References (25)

1. Alter M.J., Hadler S.C., Margolis H.S., Alexander W.J., Hu P.Y., Judson F.N., Mares A., Miller J.K., Moyer L.A. The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies. JAMA. 263:(9):1990;1218-1222.
2. Batki S.L., Gruber V.A., Bradley J.M., Bradley M., Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend. 66:(3):2002;283-293.
3. Broadhead R.S., Heckathorn D.D., Weakliem D.L., Anthony D.L., Madray H., Mills R.J., Hughes J. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Pub. Health Rep. 113:(Suppl. 1):1998;42-57.
4. Chaisson R.E., Barnes G.L., Hackman J., Watkinson L., Kimbrough L., Metha S., Cavalcante S., Moore R.D. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am. J. Med. 110:(8):2001;610-615.
5. Chaisson R.E., Keruly J.C., McAvinue S., Gallant J.E., Moore R.D. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J. Acquir. Immune Defic. Syndrome Human Retrovirol. 11:(5):1996;455-459.
6. Deren S., Stephens R., Davis W.R., Feucht T.E., Tortu S. The impact of providing incentives for attendance at AIDS prevention sessions. Pub. Health Rep. 109:(4):1994;548-554.
7. Diclemente R., Wingood G.M. Monetary incentives: a useful strategy for enhancing enrollment and promoting participation in HIV/STD risk reduction interventions. Sex Transm. Infect. 74:(4):1998;239-240.
8. Dowling-Guyer S., Johnson M.E., Fisher D.G., Needle R., Watters J.K., Anderson M., Williams M., Kotranski L., Booth R., Rhodes F., Weatherby N., Estrada A.L., Fleming D., Deren S., Tortu S. Reliability of drug users' self-reported HIV risk behaviors and validity of self-reported recent drug use. Assessment. 1:1994;383-392.
9. Francis D.P. The public's health unprotected. Reversing a decade of underutilization of hepatitis B vaccine. JAMA. 274:(15):1995;1242-1243.
10. Francis D.P., Gregory T., McElrath M.J., Belshe R.B., Gorse G.J., Migasena S., Kitayaporn D., Pitisuttitham P., Matthews T., Schwartz D.H., Berman P.W. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res. Human Retroviruses. 14:(Suppl. 3):1998;S325-S331.
11. Giuffrida A., Torgerson D. Should we pay the patient? Review of financial incentives to enhance patient compliance. Br. Med. J. 315:1997;703-707.
12. Harrison K., Vlahov D., Jones K., Charron K., Clements M.L. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J. Acquir. Immune Defic. Syndrome. 10:(3):1995;386-390.
13. Heimer R., Clair S., Grau L.E., Bluthenthal R.N., Marshall P.A., Singer M. Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction. 97:(10):2002;1277-1287.
14. Koblin B.A., Heagerty P., Sheon A., Buchbinder S., Celum C., Douglas J.M., Gross M., Marmor M., Mayer K., Metzger D., Seage G. Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 12:(7):1998;785-793.
15. Koblin B.A., Holte S., Lenderking B., Heagerty P. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET vaccine preparedness study protocol team. J. Acquir. Immune Defic. Syndrome. 24:(5):2000;451-457.
16. Kral A.H., Bluthenthal R.N., Lorvick J., Gee L., Bacchetti P., Edlin B.R. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 357:(9266):2001;1397-1401.
17. Levine O., Vlahov D., Koehler J., Cohn S., Spronk A., Nelson K. Seroepidemiology of hepatitis B virus in a population of injecting drug users: association with drug injection patterns. Am. J. Epidemiol. 142:(3):1995;331- 341.
18. Lorvick J., et al. Incentives and accessibility: a pilot study to promote TB prophylaxis in a high-risk community. J. Urban Health. 76:(4):1999;461-467.
19. Meyers K., Metzger D.S., McLellan A.T., Navaline H., Sheon A.R., Woody G.E. Will preventive HIV vaccine efficacy trials be possible with female injection drug users? J. Acquir. Immune Defic. Syndrome Human Retrovirol. 10:(5):1995;577-585.
20. Seal K.H., Ochoa K.C., Hahn J.A., Tulsky J.P., Edlin B.R., Moss A.R. Risk of hepatitis B infection among young injection drug users in San Francisco: opportunities for intervention. West J. Med. 172:(1):2000;16-20.
21. Seal, K.H., Lorvick, J., Moore, J., Thawley, R., Hammond, J.P., Gann, D., and Edlin, B.R., 2000a. Incentives for research involving liver biopsy in HCV-infected injection drug users: ethical and practical considerations (Session#6014). 128th Annual Meeting of the American Public Health Association, Boston, Massachusetts, 12-16 November 2000 (oral presentation).
22. Silva A.E., McMahon B.J., Parkinson A.J., Sjogren M.H., Hoofnagle J.H., Di Bisceglie A.M. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin. Infect. Dis. 26:(4):1998;895-897.
23. Tulsky J.P., Pilote L., Hahn J.A., Zolopa A.J., Burke M., Chesney M., Moss A.R. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch. Intern. Med. 160:(5):2000;697-702.
24. Vlahov D. HIV vaccines for injection drug users in the context of a comprehensive prevention agenda. AIDS. Res. Human Retroviruses. 10:(Suppl. 2):1994;S3-S6.
25. Watters J.K., Needle R., Brown B.S., Weatherby N., Booth R., Williams M. The self-reporting of cocaine use. JAMA. 268:(17):1992;2374-2375.